Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een onderzoek naar de werkzaamheid, veiligheid en verdraagbaarheid van LXE408 bij deelnemers met chronische ziekte van Chagas.

9 november 2026 bijgewerkt door: Novartis Pharmaceuticals

Een gerandomiseerde, door deelnemers en onderzoekers geblindeerde, gecontroleerde, parallelle groepsstudie om de werkzaamheid, veiligheid, verdraagbaarheid, farmacokinetiek en farmacodynamiek van LXE408 te beoordelen bij deelnemers met chronische ziekte van Chagas zonder ernstige orgaandisfunctie.

This study is to investigate the ability of LXE408 to clear or reduce the level of parasites in the blood of people with chronic Chagas disease. Participants must have chronic Chagas disease without severe organ dysfunction.

Studie Overzicht

Gedetailleerde beschrijving

This is an interventional, phase 2, PoC (Proof of Concept) randomized, participant- and investigator-blinded, controlled, parallel group study, with 4 treatment arms. The purpose of this study is to assess the efficacy (anti-parasitological activity), safety, PK (pharmacokinetics), and PD (pharmacodynamics) of LXE408 in participants with CICD (chronic indeterminate Chagas disease) and chronic Chagas disease without severe cardiac or gastrointestinal dysfunction compared to placebo and to benznidazole.

Studietype

Ingrijpend

Inschrijving (Geschat)

130

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

  • Naam: Novartis Pharmaceuticals
  • Telefoonnummer: +41613241111

Studie Locaties

      • Caba, Argentinië, C1015ABO
        • Werving
        • Novartis Investigative Site
      • Corrientes, Argentinië, W3400CDS
        • Werving
        • Novartis Investigative Site
      • Formosa, Argentinië, P3600KGC
        • Werving
        • Novartis Investigative Site
    • Buenos Aires
      • CABA, Buenos Aires, Argentinië, C1221ADC
        • Werving
        • Novartis Investigative Site
      • CABA, Buenos Aires, Argentinië, C1407FWE
        • Werving
        • Novartis Investigative Site
    • Córdoba Province
      • Córdoba, Córdoba Province, Argentinië, X5016KEH
        • Werving
        • Novartis Investigative Site
    • Minas Gerais
      • Montes Claros, Minas Gerais, Brazilië, 39401-001
        • Werving
        • Novartis Investigative Site
    • Pernambuco
      • Recife, Pernambuco, Brazilië, 50100-060
        • Werving
        • Novartis Investigative Site
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brazilië, 90601-000
        • Werving
        • Novartis Investigative Site
    • Rio de Janeiro
      • Rio de Janeiro, Rio de Janeiro, Brazilië, 21040-360
        • Werving
        • Novartis Investigative Site
    • São Paulo
      • São Caetano do Sul, São Paulo, Brazilië, 09521-160
        • Werving
        • Novartis Investigative Site
      • São Paulo, São Paulo, Brazilië, 01232-010
        • Werving
        • Novartis Investigative Site
      • Bogotá, Colombia, 110131
        • Werving
        • Novartis Investigative Site
      • Bogotá, Colombia, 111411
        • Werving
        • Novartis Investigative Site
      • Floridablanca, Colombia, 681017
        • Werving
        • Novartis Investigative Site
      • San Gil, Colombia, 684031
        • Werving
        • Novartis Investigative Site
    • Atlántico
      • Barranquilla, Atlántico, Colombia, 080005
        • Werving
        • Novartis Investigative Site
    • Casanare Department
      • Yopal, Casanare Department, Colombia, 850009
        • Actief, niet wervend
        • Novartis Investigative Site
    • California
      • Sylmar, California, Verenigde Staten, 91342
        • Werving
        • Olive View UCLA Educ and Res Ins
        • Hoofdonderzoeker:
          • Jonathan Soverow
        • Contact:
    • Florida
      • Gainesville, Florida, Verenigde Staten, 32610-0486
        • Werving
        • University of Florida Shands
        • Hoofdonderzoeker:
          • Norman Beatty
        • Contact:
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02118
        • Werving
        • Boston Medical Center
        • Hoofdonderzoeker:
          • Dan Bourque
        • Contact:
    • Texas
      • Houston, Texas, Verenigde Staten, 77030-3411
        • Werving
        • Baylor College of Medicine
        • Hoofdonderzoeker:
          • Eva Clark
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 60 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Male or female participants aged ≥ 18 years to ≤ 60 years old
  • Confirmed diagnosis of T. cruzi infection
  • History that participant has been determined to be in chronic phase of CD
  • Written informed consent must be obtained before any assessment is performed, and participants should express understanding of the consent form and the study
  • Participants must be considered by the investigator eligible for and able to comply with local prescribing information for benznidazole
  • Ability and willingness to communicate well with the investigator/study site and comply with requirements of the study

Exclusion Criteria:

  • Signs (on physical examination) and/or symptoms of CD in the acute phase as determined by the investigator at screening

  • History of CD treatment with benznidazole or nifurtimox at any time in the past

  • History of and/or current (at screening) symptoms or signs (physical examination findings) of moderate or severe CD-related gastrointestinal disease

  • Participants who weigh < 50 kg or >90kg at screening

  • At sites conducting the MRI assessments, participants may participate in the overall study, but will be excluded from the MRI assessment if they have contraindications to MRI imaging

  • Any clinically significant disease during screening that, in the opinion of the investigator, would put the safety of the participant at risk through participating, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study, or would compromise participant compliance or preclude completion of the study

  • Documented history or current findings at screening of clinically significant cardiovascular conditions such as, but not limited to: unstable ischemic heart disease; NYHA Class III/IV heart failure (due to Chagas disease or other conditions); arrhythmias

  • Known or suspected ongoing, chronic or recurrent viral, bacterial or fungal infectious diseases including but not limited to: Tuberculosis, leishmaniasis, severe malaria, atypical mycobacterial infection, listeriosis, aspergillosis, or endemic mycoses, and/or documented positivity for human immunodeficiency virus (HIV) infection.

    • Participants with controlled HIV on antiretroviral therapy are eligible to participate if CD4 ≥ 500 at screening
  • History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years prior to screening (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed)

  • Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the participant during the study period

    • Pancreatic injury or pancreatitis: If any single parameter of amylase or lipase exceeds 1.5x ULN at screening Participants with known recurrent pancreatitis (more than 1 episode in lifetime, from any cause) are excluded
    • Liver disease or liver injury as indicated by abnormal liver function tests (LFTs):

Any single parameter of ALT, AST, alkaline phosphatase must not exceed 1.5x ULN at screening Serum bilirubin must not exceed the ULN at screening elevated serum bilirubin is not excluded if there is a documented history of Gilbert's Syndrome

  • History of renal disease as indicated by creatinine level above 1.5x ULN or microalbuminuria at screening; Evidence of urinary obstruction, or difficulty in voiding at screening; evidence of congenital renal abnormalities with known effect on renal function; calculated eGFR <60 mL/min (<0.835 mL/s) using the CKD-EPI formula for adults

    • Participants with screening hematology parameters outside of the thresholds
    • Current use of medications prohibited by the protocol at screening and/or baseline visits, or expected use of any prohibited medication during the study treatment period
  • Use of benznidazole in the blinded arms is prohibited until unblinding occurs after all participants complete Month 12.

    • Use of other investigational drugs at the time of study drug dosing
    • History of multiple and recurring allergies or allergy to the investigational compound/compound class being used in this study or to benznidazole
    • History of drug abuse or unhealthy alcohol use within the 12 months prior to dosing
    • Pregnant or nursing (lactating/breast-feeding) women
    • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 5 days after stopping of investigational drug and benznidazole
    • Participants who, in the opinion of the investigator, will not be able to comply with study procedures or visits, adhere to dosing schedule, or other otherwise be in compliance with study requirements

Other protocol-defined inclusion/exclusion criteria may apply.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: LXE408 28 days

LXE408 administered by oral route

Experimenteel: LXE408 14 days and Placebo 14 days

LXE408 administered by oral route, followed by Placebo administered by oral route

LXE408 administered by oral route

Placebo administered by oral route

Placebo-vergelijker: Placebo 28 days

Placebo administered by oral route

Placebo administered by oral route

Actieve vergelijker: Benznidazole 60 days

Benznidazole administered by oral route

Benznidazole administered by oral route (administered as standard of care)

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Presence or absence of sustained parasitological clearance using polymerase chain reaction (PCR) results over 6 months - LXE408 28 days versus placebo.
Tijdsspanne: At Months 2, 4, and 6

The parasitological load will be measured using polymerase chain reaction (PCR) at 2 months, 4 months, and at 6 months. At each timepoint, multiple samples are evaluated. The participant will be considered negative at a visit if the parasite is not detectable in all samples at a visit and positive if the parasite level is detectable in at least one sample. Sustained parasitological clearance is achieved if participant is negative at all 3 visits.

At Months 2, 4, and 6

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Presence or absence of sustained parasitological clearance using polymerase chain reaction (PCR) results over 6 months - LXE408 -14 days versus placebo
Tijdsspanne: At Months 2, 4, and 6

The parasitological load will be measured using polymerase chain reaction (PCR) at 2 months, 4 months, and at 6 months. At each timepoint, multiple samples are evaluated. The participant will be considered negative at a visit if the parasite is not detectable in all samples at a visit and positive if the parasite level is detectable in at least one sample. Sustained parasitological clearance is achieved if participant is negative at all 3 visits.

At Months 2, 4, and 6
Presence or absence of sustained parasitological clearance using polymerase chain reaction (PCR) results over 6 months-LXE408 - 28 days and 14 days versus benznidazone
Tijdsspanne: At Months 2, 4, and 6

The parasitological load will be measured using polymerase chain reaction (PCR) at 2 months, 4 months, and at 6 months. At each timepoint, multiple samples are evaluated. The participant will be considered negative at a visit if the parasite is not detectable in all samples at a visit and positive if the parasite level is detectable in at least one sample. Sustained parasitological clearance is achieved if participant is negative at all 3 visits.

At Months 2, 4, and 6
Presence or absence of early parasitological clearance
Tijdsspanne: At Day 7, 14 and 28

The parasitological load will be measured using polymerase chain reaction (PCR). The participant will be considered negative at a visit if the parasite is not detectable in all samples at a visit and positive if the parasite level is detectable in at least one sample.

At Day 7, 14 and 28
Presence or absence of sustained parasitological clearance over 12 months by PCR testing
Tijdsspanne: 12 Months

The parasitological load will be measured using polymerase chain reaction (PCR). The participant will be considered negative at a visit if the parasite is not detectable in all samples at a visit and positive if the parasite level is detectable in at least one sample. Sustained parasitological clearance is achieved if participant is negative at all subsequent visits.

12 Months
Time to parasitological clearance based on serial PCR testing
Tijdsspanne: 12 Months

Time to parasitological clearance based on PCR by treatment will be estimated using the Kaplan-Meier approach.

12 Months
Presence or absence of seroreversion using conventional serology
Tijdsspanne: At Month 6 and Month 12

Seroreversion as measured by conventional serology will be evaluated at 6 and 12-month study visits. Seroreversion is determined by the proportion of participants achieving serology changes from positive at baseline to negative at each time point.

At Month 6 and Month 12
Occurrence and severity of treatment emergent adverse events during the study
Tijdsspanne: Up to 12 Months

Incidence and severity of AEs by treatment group, including changes in the vital signs, electrocardiogram and laboratory results qualifying and reported as AEs.

Up to 12 Months
Occurrence of adverse events resulting in treatment discontinuation
Tijdsspanne: Up to 12 Months

Incidence of AEs that result in treatment discontinuation.

Up to 12 Months
Occurrence of all-cause mortality through end of study visit
Tijdsspanne: Up to 48 Months

Incidence of death through the end of study visit.

Up to 48 Months
Maximum plasma concentration (Cmax) of LXE408
Tijdsspanne: At Day 1, 7, 14, 28

Cmax is defined as the maximum (peak) observed concentration following a dose.

At Day 1, 7, 14, 28
Time to maximum plasma concentration (Tmax) of LXE408
Tijdsspanne: At Day 1, 7, 14, 28

Tmax is defined as the time to reach maximum (peak) concentration following a dose.

At Day 1, 7, 14, 28
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8)
Tijdsspanne: At Day 1, 7, 14, 28

AUC0-8 will be calculated by non-compartmental methods based on LXE408 plasma concentration data.

At Day 1, 7, 14, 28
Pre-dose concentration
Tijdsspanne: At Day 14 and Day 28

Pre-dose concentration is the observed plasma concentration that is just prior to the beginning of, or at the end of a dosing interval.

At Day 14 and Day 28

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

28 april 2025

Primaire voltooiing (Geschat)

22 juli 2027

Studie voltooiing (Geschat)

21 januari 2031

Studieregistratiedata

Eerst ingediend

7 oktober 2024

Eerst ingediend dat voldeed aan de QC-criteria

7 oktober 2024

Eerst geplaatst (Werkelijk)

9 oktober 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

10 november 2026

Laatste update ingediend die voldeed aan QC-criteria

9 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren